Subscribe to our newsletter and stay informed

Check out our list of top companies

Check out our carefully compiled lists of the most relevant and impactful companies within their fields.

Check out our list of top unicorns

Read and learn about the biggest companies that various countries have produced, how they made it, and what the future looks like for them.
January 5, 2024

Apollo Therapeutics Soars to New Heights with $33.5 Million in Series C Funding

Proudly headquartered in the intellectual hub of Cambridge, in a Series C funding round with a infusion of $33.5 million

In a resounding testament to its groundbreaking work, Cambridge-based biopharmaceutical startup Apollo Therapeutics has not just closed the chapter on 2023 but wrapped it up with an emphatic exclamation point. The completion of the second close of its Series C round injected an additional $33.5 million, propelling the company's total funding to a formidable $260 million. Join us as we unravel the dynamic developments in Apollo Therapeutics' journey and the significant plans fueled by this fresh injection of funds.

Led by Patient Square Capital, the Series C round showcased the allure of Apollo Therapeutics, drawing support from a roster of new investors, including M&G plc and two of the largest US public pension plans. Existing investors, such as Rock Springs Capital, added their weight to this financial crescendo. But what sets Apollo Therapeutics apart isn't just the impressive funding; it's the strategic vision and purpose behind these financial maneuvers.

Apollo Therapeutics, under the stewardship of CEO Richard Mason, is not your typical biopharmaceutical entity. Its unique portfolio model adopts a 'hub-and-spoke' approach, seamlessly integrating various experts in pharmaceutical research, manufacturing, commercial strategy, fundraising, and business development. This collaborative model, borrowing best practices from both big pharma and venture capital, promises heightened focus at the individual asset level, centralized expertise, operational efficiencies, and an undeniable allure for top-tier talent.

With a commitment to translating fundamental medical research into tangible medicines, Apollo Therapeutics is set to deploy the fresh funds to propel its pipeline programs through clinical development. Additionally, it aims to fortify its drug discovery and development activities, leveraging breakthroughs made in basic medical research at its partner institutions. The company is also eyeing strategic licensing or acquisition of clinical-stage programs adhering to stringent selection criteria.

As the curtain rises on a new year, Apollo Therapeutics stands poised for an exhilarating journey ahead. CEO Dr. Richard Mason expressed gratitude for the unwavering support from existing investors and extended a warm welcome to new shareholders. With over 20 uncorrelated therapeutic programs in its expansive pipeline, multiple assets poised to enter the clinic in early 2024, and a diversified portfolio designed for risk mitigation, Apollo Therapeutics promises an exciting chapter in biopharmaceutical innovation. The second close of its Series C financing not only signifies financial prowess but is a resounding vote of confidence in Apollo Therapeutics' pioneering efforts to bring transformative medicines from research labs to real-world impact.

Josefina Dipaolo
Josefina Dipaolo
Content writer at TechNews180
Back to top

Related articles

chevron-down linkedin facebook pinterest youtube rss twitter instagram facebook-blank rss-blank linkedin-blank pinterest youtube twitter instagram